dc.contributor.author |
Buma, D. |
|
dc.contributor.author |
Bakari, M. |
|
dc.contributor.author |
Fawzi, W. |
|
dc.contributor.author |
Mugusi, F. |
|
dc.date.accessioned |
2016-09-14T07:09:50Z |
|
dc.date.available |
2016-09-14T07:09:50Z |
|
dc.date.issued |
2015-10 |
|
dc.identifier.citation |
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV. Prevention of HIV-1 infection with early antiretroviral therapy. New England journal of medicine. 2011 Aug 11;365(6):493-505. |
en_GB |
dc.identifier.issn |
2380-5536 |
|
dc.identifier.uri |
http://hdl.handle.net/123456789/2062 |
|
dc.description.abstract |
Background: Disclosure of HIV status pose a great challenge in many societies due to associated stigma. We prospectively investigated
whether or not HIV-status disclosure before commencement of antiretroviral therapy (ART) has influence on adherence, immunological response
and viral load suppression (VLS) in HIV-infected patients.
Methods: Using systematic sampling, 520 HIV-infected patients were selected prior to initiation of ART from 4 HIV care and treatment clinics
(CTC) in Dar-es-Salaam. Data on HIV status disclosure and adherence were collected using a structured questionnaire, while viral load and
CD4+ T-cell counts were determined through laboratory investigations. Patients were followed up for one year. We performed logistic regression
to determine the association between HIV status disclosure and the outcomes.
Results: Four hundred and sixty two patients were analyzed, of whom 136 (29.4%) were males. Sixty (13%) and 310 (67.1%) of the study
patients disclosed their HIV-status early and late respectively, while 92 (19.9%) did not disclose their HIV-status. Between males and females
in each category, male had low number of HIV-status disclosure, p<0.05. The proportion adhering to therapy of 96.7% was higher in patients
who disclosed their HIV-status before ART initiation compared to that of 85.4% among those who disclosed later on, p=0.0109. There was a
statistically significant difference in terms of CD4+ T-cell counts recovery between patients who disclosed earlier and those who disclosed later
on, p=0.0341. A statistically significant difference in terms of viral load suppression was also noted between early and later HIV status disclosure,
p=0.0036.
Conclusion: Disclosure of HIV-status before initiation of ART improves patients’ adherence, and has a positive influence on CD4+ T-cell
counts recovery as well as viral load suppression. |
en_GB |
dc.language.iso |
en |
en_GB |
dc.publisher |
SciForschen |
en_GB |
dc.relation.ispartofseries |
O p e n h u b f o r s c i e n t i f i c r e s e a r c h; |
|
dc.subject |
Early HIV-status disclosure |
en_GB |
dc.subject |
Adherence; CD4+T-cell counts recovery |
en_GB |
dc.subject |
Viral load suppression |
en_GB |
dc.subject |
Tanzania |
en_GB |
dc.title |
The Influence of HIV-Status Disclosure on Adherence, Immunological and Virological Outcomes among HIV-Infected Patients Started on Antiretroviral Therapy in Dar-es- Salaam, Tanzania |
en_GB |
dc.type |
Article |
en_GB |